NCT04161651

Brief Summary

Evaluation of Long-Term Implanted Sensor in Patients on Quality of life

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2019

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

November 10, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 13, 2019

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2020

Completed
Last Updated

November 20, 2019

Status Verified

November 1, 2019

Enrollment Period

11 months

First QC Date

November 10, 2019

Last Update Submit

November 18, 2019

Conditions

Keywords

eversensetype 1 diabetes

Outcome Measures

Primary Outcomes (1)

  • changes in quality of life evaluated questionnaires (DTSQ)

    6 months

Secondary Outcomes (8)

  • Change in HBA1C

    3 / 6 months

  • CGM Time In Range (70-180 mg/dl)

    3 / 6 months

  • CGM Time in hypoglycaemia below 70 mg/dl

    3 / 6 months

  • CGM Time in hypoglycaemia below 54 mg/dl

    3 / 6 months

  • CGM time in range difference [2 weeks before digital visit and 2 weeks after digital visit]

    3 / 6 months

  • +3 more secondary outcomes

Study Arms (1)

single arm

EXPERIMENTAL
Device: eversense

Interventions

eversenseDEVICE

eversense CGM

single arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female diagnosed with type 1 diabetes mellitus
  • Age \> 18
  • Insulin treatment for at least 1 year (Either MDI of CSII)
  • HbA1c \< 11%
  • Signing informed consent and willing to apply with study procedure

You may not qualify if:

  • History of severe hypoglycaemia in the last 3 months
  • History of DKA in the last 3 months
  • Any condition preventing or complicating the placement, operation or removal of the Sensor including upper extremity deformities or skin condition
  • Female subjects of childbearing capacity (defined as not surgically sterile or not menopausal for ≥ 1 year) who are lactating or pregnant, intending to become pregnant, or not practicing birth control during the course of the study
  • Any condition that require MRI imaging or planned MRI during the trial period
  • Known topical or local anaesthetic allergy
  • Known allergy to glucocorticoids
  • History of hepatitis B, hepatitis C or HIV
  • Any Bleeding disorder or taking anticoagulant medication
  • Participation in other clinical trial
  • Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2019

First Posted

November 13, 2019

Study Start

November 1, 2019

Primary Completion

October 1, 2020

Study Completion

October 1, 2020

Last Updated

November 20, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share